Literature DB >> 21282063

Long-term outcomes and prognostic factors of patients with surgically treated pulmonary carcinoid: our institutional experience with 104 patients.

Ertan Aydin1, Ulku Yazici, Mahmut Gulgosteren, Yetkin Agackiran, Sadi Kaya, Erkmen Gulhan, Irfan Tastepe, Nurettin Karaoglanoglu.   

Abstract

OBJECTIVE: Pulmonary carcinoid tumors are rare low-grade malignant neoplasms and constitute 2-5% of all lung tumors. In this study, we aimed to determine the clinical presentations, types of surgery, long-term treatment outcomes and survival rates of patients diagnosed with carcinoid tumor treated surgically in our clinic.
METHODS: Patients operated in our clinic between 1992 and 2008 with confirmed or suspected diagnoses of carcinoid tumors were included in our study. Patients' hospital records were retrospectively analyzed.
RESULTS: A total of 104 patients (age 19-71 years, mean 44±13 years, 2 SD) with pathologically confirmed carcinoid tumor were analyzed. A total of 84 patients (81%) were diagnosed as typical and the remaining 20 (19%) being atypical carcinoid tumor. As many as 24 patients (23%) were asymptomatic. The most frequent symptom was recurrent respiratory infection (35%). The most used surgical procedures were lobectomy (47%) and bilobectomy (16%). Mean postoperative follow-up period was 72 months (6-190 months). No surgery related mortality was noticed. As many as 15 (14%) patients died during the follow-up period. Overall 5- and 10-year survival rates were 89% and 72%, respectively. For typical carcinoid tumors, the 5- and 10-year survival rates were 92% and 83%, and for atypical carcinoids 73% and 46%, respectively (p<0.001).
CONCLUSIONS: In our study, we noticed histological subtype, stage of the disease and the type of surgery performed to be prognostic factors of carcinoid tumors. Atypical carcinoid tumors tend to be more metastatic and had worse prognosis when compared with typical carcinoid tumors. We conclude that surgery is the best treatment of choice for carcinoid tumors, especially parenchyma-sparing procedures, because of their good mid- and long-term survival rates.
Copyright © 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21282063     DOI: 10.1016/j.ejcts.2010.08.010

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  17 in total

1.  Endobronchial Treatment for Bronchial Carcinoid: Patient Selection and Predictors of Outcome.

Authors:  Ellen M B P Reuling; Chris Dickhoff; Peter W Plaisier; Veerle M H Coupé; Albert H A Mazairac; Rutger J Lely; H Jaap Bonjer; Johannes M A Daniels
Journal:  Respiration       Date:  2018-02-12       Impact factor: 3.580

Review 2.  Classification of lung neuroendocrine tumors: lights and shadows.

Authors:  Marco Volante; Gaia Gatti; Mauro Papotti
Journal:  Endocrine       Date:  2015-03-21       Impact factor: 3.633

Review 3.  Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations.

Authors:  Edward M Wolin
Journal:  Oncologist       Date:  2015-08-25

4.  Long-term outcomes and prognostic factors of patients with surgically treated pulmonary atypical carcinoid tumors: our institutional experience with 68 patients.

Authors:  Peng Song; Ruochuan Zang; Lei Liu; Xiayimaier Dan; Shugeng Gao
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

5.  Prognostic significance of histopathological factors in survival and recurrence of atypical carcinoid tumours.

Authors:  Eva-María García-Fontán; Miguel-Ángel Cañizares-Carretero; Montserrat Blanco-Ramos; Jose-María Matilla-González; Rommel Carrasco-Rodríguez; Francisco Barreiro-Morandeira; Mariano García-Yuste
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-27

6.  Concomitant lung and gastroenteropancreatic neuroendocrine tumors and the value of gallium-68 PET/CT.

Authors:  Daniel Kaemmerer; Karl Khatib-Chahidi; Richard Paul Baum; Dieter Hörsch; Norbert Presselt; Jörg Sänger; Almut Kunze; Merten Hommann
Journal:  Cancer Imaging       Date:  2011-11-26       Impact factor: 3.909

7.  Comprehensive Analysis of the Incidence and Survival Patterns of Lung Cancer by Histologies, Including Rare Subtypes, in the Era of Molecular Medicine and Targeted Therapy: A Nation-Wide Cancer Registry-Based Study From Taiwan.

Authors:  Jeffrey S Chang; Li-Tzong Chen; Yan-Shen Shan; Sheng-Fung Lin; Sheng-Yen Hsiao; Chia-Rung Tsai; Shu-Jung Yu; Hui-Jen Tsai
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

8.  18F-FDG PET/CT rarely provides additional information other than primary tumor detection in patients with pulmonary carcinoid tumors.

Authors:  Ebru Tatci; Ozlem Ozmen; Atila Gokcek; Inci Uslu Biner; Esra Ozaydin; Sadi Kaya; Nuri Arslan
Journal:  Ann Thorac Med       Date:  2014-10       Impact factor: 2.219

9.  Nodal involvement adversely affects prognosis in pulmonary carcinoid tumors.

Authors:  Demet Yaldız; Şeyda Örs Kaya; Kenan Can Ceylan
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2018-07-03       Impact factor: 0.332

10.  The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study.

Authors:  Hui-Jen Tsai; Chun-Chieh Wu; Chia-Rung Tsai; Sheng-Fung Lin; Li-Tzong Chen; Jeffrey S Chang
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.